Back to search results

Handgrip Exercise Training for Chronic Kidney Disease

This study is exploring whether regular handgrip exercise can improve blood pressure in people with chronic kidney disease (CKD). Participants will use a hand dynamometer for either isometric handgrip exercise training or sham training (a very light squeeze). The study aims to enroll 50 individuals aged 45-85 with CKD stages IIIa and IV who don't exercise regularly. Success will be measured by changes in your resting blood pressure and how much your blood pressure varies over time. The study is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
You would attend 4 visits lasting 2-3 hours and 3 visits lasting 1-2 hours. You would also perform home exercise training for 8 weeks, three times a week, squeezing a grip device four times for 2 minutes with each hand.
Compensation
Not stated in the trial record.
Follow-up
Your blood pressure will be measured at baseline and 8 weeks after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07094906

Handgrip Exercise Training and CKD

Not Yet Recruiting
NAAges 45–85Interventional
Emory University
~50 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Isometric handgrip exercise trainingSham Training

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in resting blood pressure (BP)
Measured over Baseline, 8-weeks post-intervention
+5 more outcomes measured

Conditions

Chronic Kidney Diseases

Explore related trials

Chronic Kidney Disease

NCT07094906

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Emory University

    Atlanta, Georgiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jeanie Park, MD · PRINCIPAL_INVESTIGATOR · Emory University

Who to contact

Jeanie Park, MD
[email protected]
404-727-1386
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with CKD (Stages IIIa and IV),
Ages 45-85 years who do not regularly exercise (defined as exercising less than 20 minutes twice per week), willing and able to cooperate with the protocol.
CKD Stages III and IV will be defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified CKD-EPI equations.
Patients with CKD must have stable renal function (no greater than a 20% reduction in eGFR over the prior 3 months).

Exclusion

Severe CKD (eGFR\<15 cc/minute)
Metabolic alkalosis (serum bicarbonate \> 28 meq/L)
Ongoing drug or alcohol abuse
Diabetic neuropathy
Any serious systemic disease that might influence survival
Severe anemia with hgb level \<10 g/dL
Clinical evidence of congestive heart failure or ejection fraction below 35%, symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history, treatment with central alpha agonists (clonidine)
Uncontrolled hypertension with BP greater than 170/100 mm Hg
Low blood pressure with BP less than 100/50
Pregnancy or plans to become pregnant
Current treatment with MAO inhibitors
Inability to perform handgrip exercise

What this trial measures

  • Change in resting blood pressure (BP)Baseline, 8-weeks post-intervention

    Resting BP will be recorded

  • Change in standard deviation BP variabilityBaseline, 8-weeks post-intervention

    Resting beat-to-beat BP will be continuously measured for 10 min. Then, the standard deviation, and BP variability in mmHg will be calculated

  • Change in average real BP variabilityBaseline, 8-weeks post-intervention

    Resting beat-to-beat BP will be continuously measured for 10 min. Then, the average variability in mmHg will be calculated.

  • Change in the coefficient of variation of BP variabilityBaseline, 8-weeks post-intervention

    Resting beat-to-beat BP will be continuously measured for 10 min. Then, the coefficient of variation of BP variability in % will be calculated.

  • Change in Brachial artery flow-mediated dilation (FMD)Baseline, 8-weeks post-intervention

    FMD of the brachial artery will be measured using doppler ultrasound. The image of the brachial artery will be obtained in the distal third of the arm (2-10 cm above the antecubital fossa) using a multi-frequency linear probe attached to a high-resolution Doppler US.

  • Change in Vascular stiffnessBaseline, 8-weeks post-intervention

    Vascular stiffness will be quantified as pulse wave velocity using applanation tonometry with a high-fidelity micromanometer. It will be reported in meters per second (m/s).